Haploidentical Versus Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

• Published in: HemaSphere Vol. 6; no. 11; pp. e790 - n/a
• Main Authors: Nagler, Arnon, Labopin, Myriam, Swoboda, Ryszard, Pioltelli, Pietro, Arat, Mutlu, Yakoub‐Agha, Ibrahim, Kulagin, Alexander, Maria Raiola, Anna, Ozdogu, Hakan, Risitano, Antonio, Nur Ozkurt, Zubeyde, Sanz, Jaime, Brissot, Eolia, Zina, Peric, Giebel, Sebastian, Ciceri, Fabio, Mohty, Mohamad
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA Lippincott Williams & Wilkins 01-11-2022; Lippincott, Williams & Wilkins; Wiley
• Series: HemaSphere
• Subjects: Life Sciences
• ISSN: 2572-9241; 2572-9241
• DOI: 10.1097/HS9.0000000000000790

The results of haploidentical stem cell transplantation (haploHCT) for patients with acute lymphoblastic leukemia (ALL) transplanted in active disease remain largely unknown. We retrospectively analyzed adult patients with R/R ALL who underwent haploHCT or matched sibling donor (MSD‐HCT) as a first transplantation between 2012 and 2020. The analysis comprised 274 patients, 94 had a haploHCT, and 180 had an MSD‐HCT. The median follow‐up was 32 months. The median age was 33 (range 18–76) and 37 (18–76) years in the haplo‐ and MSD‐HCT groups, respectively. Post‐transplant cyclophosphamide (PTCy) was used in 88% of haploHCT and in 4% of the MSD‐HCT group. Graft‐versus‐host disease grade III–IV was higher in haploHCT than in the MSD‐HCT group (18% versus 9%; P = 0.042). The 2‐year chronic (c) graft‐versus‐host disease rates were 17% versus 33% (hazard ratio [HR] = 0.56; P = 0.14), respectively. By multivariate analysis, relapse incidence, and leukemia‐free survival were not significatively different between the transplant groups, while nonrelapse mortality (NRM) was significantly higher (25% versus 18% at 2 years; HR = 2.03; P = 0.042) and overall survival (OS) lower (22% versus 38% at 2 years; HR = 1.72; P = 0.009) in the haploHCT group compared with the MSD‐HCT group. We conclude that the 2‐year OS of R/R ALL patients undergoing MSD transplants is significantly better than in haploHCT with a higher NRM in the latter.